In this topic, we will be talking about the importance of oncogenetics in cancer biology. Mutations in DNA can lead to the development of cancer, and genetic and genetic testing play a significant role in oncology. Here we discuss the underlying mechanisms that make oncogenes and tumor suppressors so important in oncology.
Why oncology is tightly linked to DNA mutation and genetics
DNA mutations and genetics are closely intertwined with the field of oncology, which focuses on the study and treatment of cancer. Mutations in DNA can lead to the development of cancer by altering the genes that control cell growth, division, and function. Genes, made up of DNA, provide instructions to cells on how to behave and function. Changes or alterations in genes, known as mutations, can occur during a person's lifetime or be inherited from parents. Acquired mutations, caused by different factors are the most common cause of cancer. Inherited mutations, which are present in the egg or sperm cells of a parent and passed on to their child, play a smaller role in the development of cancer but can increase the risk of certain types of cancer and are associated with hereditary cancer syndromes.
Genetics plays a crucial role in understanding the development and treatment of cancer. Genetic changes can transform healthy cells into cancerous cells over time. Inherited genetic changes can significantly increase the risk of certain types of cancer. However, inheriting a genetic change does not guarantee the development of cancer, only an increased risk. Family cancer syndromes, caused by inherited genetic variants, further illustrate the connection between genetics and cancer. For example, familial adenomatous polyposis (FAP) is a hereditary cancer syndrome caused by changes in the APC gene, which greatly increases the risk of colorectal cancer.
Genetic testing plays a significant role in oncology. Genetic tests can identify if an individual has inherited a genetic change that increases their cancer risk. Genomic analysis, which involves analyzing the genetic makeup of tumors, is also crucial in cancer treatment. It helps identify specific gene mutations associated with certain types of cancer, allowing for targeted therapies and personalized treatment approaches.
Oncogenes
Oncogenes are genes that can accelerate the onset of cancer when they undergo mutations. These genetic mutations can result in the abnormal activation of oncogenes, leading to uncontrolled cell growth and tumor formation. While normal genes regulate cell growth and division, oncogenes disrupt these processes, promoting the uncontrolled proliferation of cells. This abnormal activity of oncogenes can be triggered by various factors, including exposure to carcinogens or inherited genetic mutations. Understanding the function and regulation of oncogenes is essential for developing targeted therapies and treatment strategies for cancer patients.
Oncogenes are mutated forms of genes that can cause cancer by promoting uncontrolled cell growth and inhibiting cell death. They are derived from normal genes called proto-oncogenes, which regulate cell growth and division. When proto-oncogenes become mutated, they can transform into oncogenes, leading to the development of cancer. Activation of oncogenes can result in accelerated cell division and the formation of tumors. Additionally, oncogenes can prevent cells from undergoing programmed cell death, allowing cancer cells to survive and accumulate.
Oncogenes can be activated through various mechanisms, including gene mutations, amplification, chromosomal rearrangements, and viral infections. Once activated, they promote uncontrolled cell growth and survival, contributing to the progression and metastasis of cancer. Understanding the role of oncogenes is important for developing targeted therapies. By specifically targeting oncogenes or their signaling pathways, researchers and healthcare professionals aim to inhibit abnormal cell growth and improve cancer treatment outcomes.
Following is a list of the most relevant oncogenes in cancer biology:
1. HER2/Neu transmembrane receptor: HER2/Neu is found to be mutated in many different kinds of cancer, including breast, ovarian, and gastric carcinomas. Amplification of the HER2/Neu gene leads to an increased amount of the HER2 protein on the surface of cells, which can stimulate cell division and contribute to tumor growth.
2. RAS kinase: RAS is mutated in colon carcinoma and other cancer types. The RAS protein is involved in transmitting signals that drive cell division, and mutations in the RAS gene can lead to uncontrolled cell growth.
3. MYC kinase: MYC is associated with several cancer types, including Burkitt's lymphoma and lung tumors. The MYC gene is involved in regulating cell growth and division, and abnormal expression of MYC can promote cancer development.
4. Telomerase: The protein is involved in replicating and maintaining the ends of chromosomes. Telomerase is normally turned off in most adult tissues, but its reactivation in cancer cells allows for unlimited cell division.
These are just a few examples of important oncogenes, and there are many others that have been identified and studied. The current list of known cancer genes includes 70 genes associated with germline mutations and 342 genes associated with somatic mutations.
Tumor suppressors
Tumor suppressor genes, also known as anti-oncogenes, are normal genes responsible for regulating cell division and replication. Their main role is to slow down cell division or instruct cells to undergo programmed cell death, also known as apoptosis. Tumor suppressor genes act as "brakes" to inhibit cell proliferation and prevent the development of tumors and cancer. When a tumor suppressor gene undergoes a mutation and becomes inactivated, it can result in uncontrolled cell growth and an increased risk of cancer. This mutation leads to a loss or reduction in the production or function of the protein encoded by the tumor suppressor gene. Tumor suppressor genes are essential in maintaining proper cellular functions and protecting the body from cancer.
The two-hit hypothesis, also known as the Knudson hypothesis, proposes that most tumor suppressor genes require both genetic copies to be inactivated in order to cause cancer. According to this hypothesis, a person initially inherits one healthy copy and one damaged copy of a tumor suppressor gene. The first hit occurs when one copy is damaged, but the remaining normal copy is still functional enough to regulate cell division and prevent the formation of tumors. However, if the second hit occurs, where the normal copy also loses its function, the tumor suppressor gene is completely inactivated. This loss of function in tumor suppressor genes can lead to uncontrolled cell division, as the genes are responsible for slowing down cell division or initiating programmed cell death when necessary. When cell division is no longer properly regulated, cells can grow out of control and form tumors, contributing to cancer development.
Overall, understanding the function of tumor suppressor genes and the two-hit hypothesis helps us comprehend the underlying mechanisms of cancer development. Tumor suppressor genes play a crucial role in maintaining proper cellular functions and preventing the formation of tumors. However, when these genes are inactivated through mutations or silencing, it can result in the loss of control over cell division and contribute to the development of cancer.
Following is a list of the most relevant tumor suppressor genes in cancer biology:
1. Retinoblastoma (RB), cell cycle regulation: RB protein acts as a tumor suppressor by preventing excessive cell growth and inhibiting cell cycle progression until a cell is ready to divide. Its mutation causes pediatric tumors of the eye, hence the name.
2. TP53 (p53), cell cycle regulation: p53 protein functions as a tumor suppressor by regulating cell division and preventing cells from growing and dividing too fast or in an uncontrolled manner. It directly binds to DNA.
3. BRCA1/2, DNA repair protein: BRCA1 protein acts as a tumor suppressor by preventing cells from growing and dividing too rapidly or in an uncontrolled way. It is involved in repairing damaged DNA.
4. CDKN2A, cell cycle regulation: CDKN2A is a tumor suppressor gene that, when mutated, can increase the risk of developing melanoma, lung cancer, bladder cancer, and pancreatic cancer. It is active in the p53 pathway.
5. APC, proteasome protein: APC is a tumor suppressor gene involved in the regulation of the WNT signaling pathway. Here it degrades the oncogene beta-catenin. Mutations in the APC gene are associated with colorectal cancer and hepatocellular carcinoma.
Contrast between oncogenes and cancer-suppressing proteins
Activating mutations in proto-oncogenes and silencing mutations in tumor suppressor genes both lead to tumor development, but in a very distinct manner: oncogene-only driven tumors frequently occur in younger patients, as only one activating mutation is needed to override normal cell division regulation. If therapy is available, these tumors have a good long-term prognosis, as only one gene has become dysfunctional and can be directly targeted by treatment. In contrast and due to the two-hit hypothesis, tumor suppressor mutation-induced cancers peak in higher age groups, as it is necessary to lose two functional copies of a gene. At that time point, the genome will have already accumulated numerous mutations. Furthermore, these tumors become genetically unstable and will lead to further mutagenesis, which creates an evolutionary arms race against chemotherapeutic treatment to favor surviving cell populations. Taken together with the less functional physiology of the elderly, tumor suppressor mutated cancers present an overall unfavorable prognosis.
In summary, oncogene and tumor suppressor gene mutations lead to cancers with different characteristics. It is however important to understand that most of the time both types of mutations can be found in a single tumor and monogenetic causative events are rare in clinical oncology.
Tumor markers
Tumor markers play a vital role in the field of cancer diagnosis and management. These measurable substances, found in the blood, urine, or tissues, can indicate the presence of a tumor. Tumor markers are typically proteins or other molecules that are produced by cancer cells or by normal cells in response to the presence of cancer cells. While they are not specific to a particular type of cancer, tumor markers are essential for early detection, monitoring treatment response, and assessing the risk of cancer recurrence. Elevated levels of tumor markers do not always indicate the presence of cancer, and further diagnostic tests are needed for an accurate diagnosis. These two tumor markers are widely used:
1. Alpha-fetoprotein (AFP): AFP is a tumor marker used to detect and monitor liver cancer, as well as certain types of testicular and ovarian cancers. Elevated levels of AFP can indicate the presence of these cancers.
2. Prostate-specific antigen (PSA): PSA is a tumor marker used primarily for the detection and monitoring of prostate cancer. Elevated levels of PSA in the blood can be an indication of prostate cancer development or recurrence.
Conclusion
The close relationship between DNA mutations, genetics, and oncology is evident as mutations in DNA can lead to cancer by disrupting genes controlling cell behavior. Oncogenes, resulting from mutated proto-oncogenes, fuel uncontrolled cell growth and hinder cell death, promoting cancer. They can activate through various mechanisms and are crucial targets for therapies. In contrast, tumor suppressor genes act as brakes on cell division, and their inactivation due to mutations increases cancer risk. The two-hit hypothesis explains their function, with both alleles needing mutation to lead to cancer. Oncogene-driven tumors differ from tumor suppressor-driven ones, often arising in younger patients and responding well to treatment. Tumor markers, measurable substances indicating cancer presence, aid in diagnosis and management. Taken together an in-depth understanding of oncogenetics gives rise to novel therapy approaches and advances in clinical oncology.